ADX‑629 : Aldeyra Therapeutics kicks off atopic dermatitis phase 2 trial

American biotech company Aldeyra Therapeutics said that it has enrolled the first patient in a phase 2 clinical trial of ADX‑629 for the treatment of ... Read More